Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05/25 SANOFI : Data on Influenza Described by Researchers at Sanofi (Passive enhanced ..
05/25 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Entry into a Material ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/23 THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
05/23 SANOFI : s insulin lispro receives CHMP positive opinion to treat diabetes
05/23 SANOFI : Phony Veterinary Labels Land Michael Chihwen Wang in the Doghouse
05/22 SANOFI : and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Tre..
05/22 SANOFI SA : Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispr..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 FDA chief says agency needs to play a role in constraining drug prices by eas..
05/24 Exelixis Could Still Be A Buy
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
05/23 What Happened With The Genzyme CVR Since August 2015
Advertisement
Financials (€)
Sales 2017 36 691 M
EBIT 2017 9 442 M
Net income 2017 7 526 M
Debt 2017 3 541 M
Yield 2017 3,42%
P/E ratio 2017 14,83
P/E ratio 2018 18,18
EV / Sales 2017 3,11x
EV / Sales 2018 2,99x
Capitalization 110 539 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI13.54%123 549
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results